IBRX - ImmunityBio, Inc.


2.97
-0.080   -2.694%

Share volume: 6,011,880
Last Updated: 04-03-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.06%

PREVIOUS CLOSE
CHG
CHG%

$3.05
-0.08
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
32%
Profitability 25%
Dept financing 25%
Liquidity 74%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
-1.33%
1 Month
-1.66%
3 Months
7.61%
6 Months
-13.41%
1 Year
-47.15%
2 Year
76.79%
Key data
Stock price
$2.97
P/E Ratio 
0.00
DAY RANGE
$2.90 - $3.06
EPS 
-$0.59
52 WEEK RANGE
$2.28 - $10.53
52 WEEK CHANGE
-$47.99
MARKET CAP 
1.784 B
YIELD 
N/A
SHARES OUTSTANDING 
696.533 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.82
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$7,250,663
AVERAGE 30 VOLUME 
$5,578,269
Company detail
CEO: Richard Adcock
Region: US
Website: immunitybio.com
Employees: 590
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers.

Recent news
loading